DIMAC, empowered by our proprietary immune-modulating payload, holds the potential to open the ADC modality to a significant white-space market in autoimmune and other therapeutic areas. Current treatments for chronic autoimmune diseases often associate with severe side effects. Long term use of glucocorticoids, for example, are commonly associated with increased risks of bone fractures, weight gain, diabetes, immune system suppression, and other chronic conditions. We believe ADCs can reshape the treatment paradigm of autoimmune diseases by offering a targeted treatment with low systemic exposure, enhanced efficacy and reduced side effects. Molecules designed under our DIMAC platform have demonstrated potent and broad anti-inflammatory activity, long duration of action, sustained stability, and low systemic exposure in preclinical studies.

· Duality Immune Modulating Antibody Conjugate

· 1 clinical asset

· First-in-class ADC platform for autoimmune diseases

· “Smart steroid”, targeted delivery of steroid with limited exposure to normal tissue

· Superior to traditional antibody therapy in efficacy